

CELLECTIS

French limited liability company (*société anonyme*)
with share capital of 5.029.549,70 euros
Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris trade and companies register No. 428 859 052
(the "Company")

Information regarding the director's nominee

SHAREHOLDERS MEETING OF JUNE 25, 2026

1. **NAME AND FIRST NAME:** GARNIER, Jean-Pierre
2. **DATE AND PLACE OF BIRTH:** October 31, 1947, Le Mans, France
3. **AGE:** 78
4. **NATIONALITY:** French, American
5. **PROFESSIONAL PROFILE AND PROFESSIONAL ACTIVITIES DURING THE PAST FIVE YEARS**

Over the past five years, Dr. Jean-Pierre Garnier, former CEO of GlaxoSmithKline, has focused on strategic and governance roles in the pharmaceutical and biotechnology sectors, rather than on operational functions.

In August 2024, he was appointed chairman of the board of directors at BioAge Labs, a biotechnology company specializing in diseases related to aging and obesity.

He brings his experience in drug development and industrial strategy to the company to support clinical trials and growth.

Dr. Garnier holds an MS in pharmaceutical science and a Ph.D. in pharmacology from the Louis Pasteur University of Strasbourg, France. He subsequently earned his MBA at Stanford University, California, as a Fulbright Scholar. He was recently promoted from Chevalier to Officier de la Légion d'Honneur of France.

On-going mandates:

 - *BioAge Labs, Chairman of the Board of Directors*
 - *Carrier Global Corporation, Board member*

Other mandates and functions held during the past five years:

 - *Carmat, Chairman of the Board of Directors (2018–2022)*
 - *Radius Health, Inc., director*
6. **CURRENT POSITION IN THE COMPANY**

Director and Chairman of the Board of Directors
7. **COMPANY SHARES OWNED BY THE DIRECTOR NOMINEE**

Dr. Garnier holds 495,380 stock options that, if exercised, would entitle him to a total of 510,481 shares of the company.

CELLECTIS

French limited liability company (*société anonyme*)
with share capital of 5.029.549,70 euros
Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris trade and companies register No. 428 859 052
(the "Company")

Information regarding the director's nominee

SHAREHOLDERS MEETING OF JUNE 25, 2026

1. **NAME AND FIRST NAME:** CHARTIER, Cécile
2. **DATE AND PLACE OF BIRTH:** June 12, 1966, Désertines, France
3. **AGE :** 59
4. **NATIONALITY :** French
5. **PROFESSIONAL PROFILE AND PROFESSIONAL ACTIVITIES DURING THE PAST FIVE YEARS**

Dr. Cécile Chartier worked as the Chief Scientific Officer at NextVivo, Inc.

Prior to joining NextVivo, Dr. Chartier served as Vice President of Research at Iovance Biotherapeutics, Inc., where she led the development of next-generation tumor-infiltrating lymphocyte (TIL) therapies, from research through early clinical trials.

Dr. Cécile Chartier joined Pantheon Biosciences, a South San Francisco biotech startup, as Head of R&D in March of this year.

Dr. Cécile Chartier earned her Ph.D. in molecular biology from Louis Pasteur University in Strasbourg and completed postdoctoral training at Harvard Medical School.

On-going mandates:
None

Other mandates and functions have been held during the past five years:
None
6. **CURRENT POSITION IN THE COMPANY**
Director
7. **COMPANY SHARES OWNED BY THE DIRECTOR NOMINEE**
None

CELLECTIS

French limited liability company (*société anonyme*)
with share capital of 5.029.549,70 euros
Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris trade and companies register No. 428 859 052
(the "Company")

Information regarding the director's nominee

SHAREHOLDERS MEETING OF JUNE 25, 2026

1. **NAME AND FIRST NAME:** ARTHAUD, Laurent
2. **DATE AND PLACE OF BIRTH:** September 19, 1962, Paris, France
3. **AGE :** 63
4. **NATIONALITY :** French
5. **PROFESSIONAL PROFILE AND PROFESSIONAL ACTIVITIES DURING THE PAST FIVE YEARS**

Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies and French Tech Accélération for Bpifrance Investissement since 2012.

Since 2009 Mr. Arthaud has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program

Mr. Arthaud is a graduate of the École Polytechnique and the École Nationale de Statistique et d'Administration Économique

On-going mandates:

 - *Sparing Vision SAS, director*
 - *Kurma Life Sciences, director*
 - *Aledia, director*
 - *Enyo Pharma, director*

Other mandates and functions held during the past five years:

 - *Calyxt, director (2017-2019 and 2020-2023)*
 - *Ribogenics Inc., director (2018-2025)*
 - *Adocia, director (2009-2022)*
6. **CURRENT POSITION IN THE COMPANY**
Director
7. **COMPANY SHARES OWNED BY THE DIRECTOR NOMINEE**
None

CELLECTIS

French limited liability company (*société anonyme*)
with share capital of 5.029.549,70 euros
Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris trade and companies register No. 428 859 052
(the "Company")

Information regarding the director's nominee

SHAREHOLDERS MEETING OF JUNE 25, 2026

1. **NAME AND FIRST NAME:** BOEHM, Rainer
2. **DATE AND PLACE OF BIRTH:** May 9th, 1960, Schwaebisch Gmuend, (Germany)
3. **AGE :** 66
4. **NATIONALITY :** German
5. **PROFESSIONAL PROFILE AND PROFESSIONAL ACTIVITIES DURING THE PAST FIVE YEARS**

Mr. Boehm spent 29 years at Novartis, working locally, regionally and globally in various senior management roles, after building his career in Marketing & Sales and Medical Affairs. He led the United States and Canada as well as all emerging markets regions, either for Oncology or the Pharmaceuticals division.

Mr. Boehm has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France and is currently completing his Master of Public Health studies in Switzerland.

On-going mandates:

- *BioCopy AG, independent director*

Other mandates and functions held during the past five years:

- *Omega Therapeutics, Inc., director (2022-2025)*
- *Berlin Cure AG, director and chairman (2022-2026)*
- *Nordic Nanovector S.A., director (2018-2022)*
- *Humanigen, Inc., director (2018-2024)*

CURRENT POSITION IN THE COMPANY

Director

7. **COMPANY SHARES OWNED BY THE DIRECTOR NOMINEE**

Mr. Boehm owns 40,000 non-employee warrants that, if not exercised, will lapse in October 2027.